Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 16Triple Negative Breast Neoplasms 13Colorectal Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 7Stomach Neoplasms 6Lymphoma 6Uterine Cervical Neoplasms 5Ovarian Neoplasms 5Lung Neoplasms 4Liver Neoplasms 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Advanced Solid Tumor 3Solid Tumors 2Solid Tumor, Adult 2Recurrence 2Rectal Neoplasms 2

Interventions

Azacitidine 33venetoclax 10decitabine and cedazuridine drug combination 7Decitabine 7sabatolimab 3pevonedistat 3cedazuridine 3ON 01910 3spartalizumab 2glasdegib 2cc-486 2Panobinostat 2Cytarabine 2BI 6727 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1triciribine 1tipifarnib 1terameprocol 1tapotoclax 1tagraxofusp 1ruxolitinib 1orludodstat 1navitoclax 1lonafarnib 1lintuzumab 1lenzilumab 1guadecitabine 1exatecan 1bisantrene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Chronic × spartalizumab × Clear all
NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Novartis

Phase 2 Active not recruiting
33 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡